Background-Despite mild reductions in rates of lower extremity amputation over the past decade, few data exist on the use of arterial testing in patients before amputation. Methods and Results-Using Medicare claims from 2000 through 2010, we examined rates of preamputation arterial testing between 0 to 12 and 0 to 24 months before amputation. We used multivariable, modified Poisson regression models to identify patient and clinical predictors of preamputation arterial testing. The main outcome measures were rates of preamputation arterial testing. Among 17 463 patients undergoing nontraumatic amputation, 68.4% underwent some type of arterial testing. Of these patients, 47.5% underwent ankle-brachial index measurement, 38.7% duplex ultrasound, 31.1% invasive angiography, 6.7% computed tomographic angiography, and 5.6% magnetic resonance angiography. Temporal analysis revealed an increase in testing from 65.7% in 2002 to 69.2% in 2010 (P<0.001). The use of preamputation arterial testing varied significantly by location of amputation and was lowest for foot amputation (62.5%), followed by above-knee amputation (69.0%) and below-knee amputation (76.7%; P<0.001). After multivariable adjustment, older age, male sex, black race, renal disease, diabetes mellitus, known peripheral arterial disease, evaluation by a vascular specialist, and living in the East North Central region were associated with greater rates of preamputation arterial testing. Conclusions-Rates of evaluation for peripheral arterial disease before amputation were low, and testing varied by patient, provider, and regional characteristics. (Circ Cardiovasc Qual Outcomes. 2014;7:142-150.)
L ower extremity peripheral artery disease (PAD) affects ≈8 million people in the United States and, in its most severe form, can require lower extremity amputation. 1, 2 Lower extremity amputation is associated with significant morbidity, mortality, and healthcare costs. 3, 4 During the past decade, improved detection, screening, and treatment strategies for PAD have been associated with a declining rate of lower extremity amputation among patients with the disease. 5, 6 The possibility of improved revascularization options for patients facing lower extremity amputation is limited inherently to patients for whom the diagnosis of PAD has been considered and the arterial anatomy has been assessed. As a result, current guidelines suggest that at-risk patients should be screened with arterial testing for the diagnosis of PAD. 1 Although previous studies have examined the intensity of vascular care before amputation, these studies were limited to patients with known PAD and did not address lower extremity arterial testing. 7 Consequently, we sought to characterize the frequency and change over time in arterial testing for the identification and anatomic characterization of PAD in older patients undergoing nontraumatic lower extremity amputation.
Methods

Data Sources
We obtained data for a nationally representative 5% cohort of Medicare beneficiaries from 2000 through 2010 from the Centers for Medicare and Medicaid Services. The inpatient files contain institutional claims for facility costs covered under Medicare Part A, and the outpatient files contain claims from institutional outpatient providers (eg, ambulatory surgery centers, hospital outpatient departments). The carrier files contain noninstitutional provider claims for services covered under Medicare Part B. The denominator files contain beneficiary demographic data and information about program eligibility and enrollment. We restricted the analysis to fee-for-service Medicare beneficiaries living in the United States.
Study Population
We searched carrier claims submitted between January 1, 2002, and December 31, 2010, to identify patients who underwent any lower extremity amputation (see Table I in the Data Supplement for procedure codes). To ensure that these amputations were not a result of trauma, we omitted data for patients who had a concurrent diagnosis of traumatic amputation on the carrier claim. For patients with multiple claims for lower extremity amputation, we defined the earliest as the index procedure and required that no amputation was performed in the 12 months before the index procedure. To assess comorbid conditions and previous procedures, we required continuous enrollment in fee-for-service Medicare for 24 months before the index procedure. Because Medicare beneficiaries <65 years of age often have chronic illnesses that predispose them to PAD, and because current guidelines suggest that patients >50 years of age with risk factors are at risk for PAD, this analysis includes beneficiaries of all ages. 8
Preamputation Arterial Testing
We searched carrier claims for Current Procedural Terminology codes for ankle-brachial index (ABI) measurement, lower extremity arterial duplex ultrasound, lower extremity computed tomographic angiography, lower extremity magnetic resonance angiography, and lower extremity angiography performed on the day of amputation or in the previous 12 months to identify receipt of arterial testing before nontraumatic lower extremity amputation (Table in the Data  Supplement) . In a sensitivity analysis, we extended the preamputation testing ascertainment period to 0 to 24 months before the index procedure date.
Predictors of Preamputation Arterial Testing
Patient demographic characteristics included age, sex, race, and state and zip code of residence. We used the self-reported race categories black and white and combined all other categories as other. On the basis of state of residence, we grouped beneficiaries into 9 US census regions. We derived a rural indicator variable from rural-urban commuting area scores based on zip code of residence. 9,10 For comorbid conditions, we used previously validated coding algorithms to search inpatient, outpatient, and carrier claims in the 12 to 24 months before the index procedure for evidence of cancer, cerebrovascular disease, chronic obstructive pulmonary disease, heart failure, ischemic heart disease, dementia, diabetes mellitus, hypertension, and renal disease. 11, 12 We defined PAD on the basis of any diagnosis code or procedure code for revascularization. 7, 13 We also searched carrier claims for outpatient evaluation and management visits with a vascular specialist, excluding service in an inpatient hospital or emergency department (Table in the Data Supplement) . We identified vascular specialists using the Health Care Financing Administration specialty code on the carrier claim, including cardiologists, peripheral vascular disease specialists, vascular surgeons, and interventional radiologists (Table in the Data Supplement) .
Statistical Analysis
We present categorical variables as frequencies with percentages and continuous variables as mean with SDs. We tested for differences in patient characteristics and use of preamputation imaging by location (foot, below the knee, or above the knee) using χ 2 tests for categorical variables and Kruskal-Wallis tests for the continuous age variable, which had a nonnormal distribution. Similarly, we tested for differences in the use of preamputation imaging between patients with or without a diagnosis of PAD in the 12 to 24 months before amputation and between patients <65 and ≥65 years of age. We plotted the yearly rates of preamputation arterial testing stratified by amputation location, and we tested for temporal trends using the Cochran-Mantel-Haenszel test for nonzero correlation. We examined factors associated with receipt of preamputation arterial testing using univariate and multivariable, modified Poisson regression models. 14 In the multivariable models, we adjusted for covariates including age at amputation, sex, race, US census region, rural location, comorbid conditions in the previous year, outpatient evaluation and management visit with a vascular specialist in the previous year, and year of the index procedure.
The 2-sided significance level was 0.05. We used SAS version 9.2 for all analyses. The institutional review board of the Duke University Health System approved the study.
Results
Overall, we identified 17 463 patients who underwent nontraumatic lower extremity amputation between 2002 and 2010. These amputations included 7343 (42%) foot amputations, 4804 (27.5%) below-knee amputations, and 5316 (30.4%) above-knee amputations. Table 1 shows the demographic and clinical characteristics of the cohort.
Among patients who underwent nontraumatic lower extremity amputation, the mean age was 73.8 years, 49.1% were women, and 71.8% were white. In the 12 to 24 months before amputation, 54.1% of patients had PAD, 47% had ischemic heart disease, 35.4% had heart failure, 62.8% had diabetes mellitus, and 27.7% had renal disease. About one third of patients were seen by a vascular specialist and 26.6% were seen by a cardiologist.
Preamputation arterial testing was performed in 68.4% of all patients undergoing nontraumatic lower extremity amputation between 2002 and 2010. The median time from arterial testing to amputation was 14 days (interquartile range, 4-50). Rates were significantly different among patients undergoing foot (62.5%), below-knee (76.7%), and above-knee (62.5%) amputations (P<0.001; Table 2 ). The rate of preamputation ABI measurement was 47.5% overall and was significantly different between the groups (46.1%, 52.9%, and 44.5%; P<0.001). Extending the period of ascertainment for preamputation arterial testing from 0 to 12 months to 0 to 24 months before amputation did not change the relative frequencies of arterial testing. The use of preamputation arterial testing among patients ≥65 years of age was higher than among those <65 years of age (69.2% versus 65.1%; P<0.001; Table 3 ). The median time from arterial testing to amputation was 14 days (interquartile range, 4-57) among patients <65 years of age and 14 days (interquartile range, 4-49) among patients ≥65 years of age.
WhAT IS KnOWn
• Improvements in detection, screening, and treatment strategies for peripheral arterial disease have been associated with a declining rate of lower extremity amputation. • The possibility of improved revascularization in patients facing lower extremity amputation is limited to patients for whom a diagnosis of peripheral arterial disease has been considered and the arterial anatomy has been assessed. Thus, guidelines suggest that at-risk patients should be screened with arterial testing for a diagnosis of peripheral arterial disease.
WhAT ThE STUDY ADDS
• Many patients, both with and without known peripheral arterial disease, underwent lower extremity amputation without arterial testing in the year before amputation. • Consistent with underrecognition and undertreatment of peripheral arterial disease in women, women were less likely to receive preamputation arterial testing. • Younger patients and patients living in rural areas also were less likely to receive preamputation arterial testing. To assess changing practice patterns, we examined the frequency of preamputation arterial testing over time ( Figure 1) . Although there was a significant increase in arterial testing overall during the study period (65.7% in 2002 versus 69.2% in 2010; P<0.001), rates remained <80% for both above-knee and below-knee amputations. Preamputation arterial testing in foot amputations remained consistent during the study period at ≈62%. Specifically, there was a statistically significant increase in the rate of preamputation ABI measurement (43.8%-49%), duplex ultrasound (25.4%-37.5%), and computed tomographic angiography (0.4%-12.9%). There was no statistically significant change in invasive angiography (39.3%-39.1%), and there was a significant decrease in preamputation magnetic resonance angiography (3.1%-1.9%; Figure 2 ). Table 4 summarizes the frequency of preamputation arterial testing by previous PAD diagnosis in patients undergoing lower extremity amputation. Any arterial testing (73.7% versus 62.1%; P<0.001) and ABI measurement (52.8% versus 41.2%) were more frequent in patients with known PAD. Among patients with known PAD, anatomic arterial testing, defined as duplex ultrasound, computed tomographic angiography, magnetic resonance angiography, or invasive angiography, occurred in 34.8%, 6.8%, 6.3%, and 42.1%, respectively. Extending the ascertainment period for arterial testing to 2 years before amputation did not change the frequency of testing substantially in patients without PAD (62.1% versus 62.5%). Table 5 shows the results of the Poisson models created to identify clinical predictors of preamputation arterial testing. After multivariable adjustment, younger age, female sex, dementia, Mountain region, and rural location were associated with lower likelihoods of undergoing preamputation arterial testing. Black race, renal disease, diabetes mellitus, known PAD, and previous evaluation by a vascular specialist were associated with greater likelihoods of preamputation arterial testing.
Discussion
Treatment options for PAD are expanding but are limited to patients for whom a diagnosis of PAD has been made. In our study of Medicare beneficiaries who undergo nontraumatic lower extremity amputation, only 68.4% received peripheral arterial testing of any kind in the preceding 12 months, including basic testing such as ABI measurement. Preamputation testing was associated with age, race, sex, diabetes mellitus, renal disease, PAD status, geography, and previous evaluation by a vascular specialist. Despite publication of the first American College of Cardiology/American Heart Association guidelines for PAD and a concurrent PAD awareness campaign by the National Heart, Lung, and Blood Institute in 2005 to 2006, rates of preamputation arterial testing improved only modestly (65.7% versus 69.2%) between 2002 and 2010. Although declining in incidence, lower extremity amputation still carries a significant burden of morbidity and economic cost for individual patients. 1, 3, 4 As a result, current guidelines state that lower extremity amputation, at least in part, because of arterial insufficiency is reserved for patients without medical or revascularization options. 1 These guideline recommendations rest on the assumption that clinicians will identify accurately the presence and pathological contribution of arterial insufficiency to an extremity under consideration for nontraumatic amputation.
Previous studies have highlighted the difficulty of relying on patient history and physical examination alone for the diagnosis of PAD in patients with or without lower extremity symptoms. 15 In light of its high sensitivity and specificity, 16, 17 correlation with disease severity, 18 ability to predict future cardiovascular events, 19 ease of performance, and low cost, the ABI has long been considered the gold standard for the diagnosis of PAD. Although not specifically validated as a screening tool in patients undergoing nontraumatic amputation, given the cost, morbidity, and decrement in quality of life associated with lower extremity amputation, [20] [21] [22] the threshold for measurement of the ABI should be low. For these reasons, the PAD guidelines recommend ABI as part of the initial management of patients undergoing amputation. 1 The optimal amount of preamputation arterial testing has yet to be defined based on test characteristics, outcomes studies, and cost-effectiveness studies. Patients with poor functional status have had poorer outcomes with surgical revascularization 23, 24 ; however, there is disagreement about what represents a salvageable limb. 25 Given the proven benefit of revascularization in amputation-free survival and quality of life, [26] [27] [28] [29] it seems that arterial testing should be offered to most patients facing lower extremity amputation. Indeed, small studies have demonstrated favorable 1-year survival and amputation-free survival with the use of aggressive screening and revascularization programs in patients facing amputation. 30 Despite these recommendations and data, we observed a rate of preamputation ABI measurement of only 47.5% and an overall arterial testing rate of 68.4%. The change in overall preamputation arterial testing from 2002 to 2010 was clinically negligible, despite a statistically and clinically significant increase in preamputation ultrasound and computed tomographic angiography. Given that the magnitudes of increase in duplex ultrasound and computed tomographic angiography were greater than the magnitude of change in overall preamputation arterial testing, it is likely that a subset of patients received multiple tests, perhaps indicating attempts at preamputation revascularization. This disproportionate increase in the rate of preamputation anatomic imaging in the face of relatively unchanged overall preamputation arterial testing rates is consistent with previously described differences in the intensity of vascular care. 7 Although patients undergoing above-knee amputation lose more tissue and have a larger decrement in mobility than patients undergoing above-knee amputation, the rates of preamputation arterial testing were lower among patients undergoing above-knee amputation. The reasons for this discrepancy are unclear. If the observed testing rates in patients undergoing above-knee amputation correlate with arterial testing rates in all patients being considered for above-knee amputation, then the discrepancy may be a reason that aboveknee amputation continues to occur 30% more frequently than below-knee amputation. 5 Stratification of preamputation arterial testing rates by PAD diagnosis revealed that, even in patients with known PAD, arterial testing occurs in <75% of patients and anatomic arterial testing occurs in even fewer. Current guidelines suggest that if a patient facing amputation is considered a candidate for revascularization, then the patient should undergo anatomic arterial testing. 1 However, unlike surgical revascularization, there is little evidence-based guidance on nonanatomic predictors of successful endovascular revascularization. Thus, clinicians who choose not to obtain initial or repeat anatomic testing in patients with known PAD presenting for consideration of lower extremity amputation may be missing an opportunity to prevent amputation.
Despite potentially missing opportunities to prevent amputation, our findings that black patients and patients with renal disease, PAD, and diabetes mellitus are more likely to receive preamputation arterial testing imply that clinicians are indeed focusing testing on patients with the highest pretest likelihoods of PAD. 31 These same patients are less likely to receive attempted revascularization, 7 implying that this discrepancy in care is not because of a lack of recognition of PAD but rather the extent of disease or procedure-related factors. Our finding that women are less likely to receive preamputation arterial testing is consistent with a recent American Heart Association scientific statement outlining the underrecognition and undertreatment of PAD in women. 32 We included patients <65 years of age in this analysis because guidelines suggest an elevated risk of PAD in patients >50 years of age with risk factors. 8 Although patients <60 years of age were also less likely to undergo preamputation arterial testing, this finding should be interpreted with caution. Because of fee-for-service Medicare eligibility requirements, enrolled patients <65 years of age are more likely to be permanently disabled or be on dialysis. Thus, our findings may be consistent with clinicians forgoing arterial testing because of perceived lack of candidacy for revascularization or a lack of recognition of PAD in younger patients.
Although rates of revascularization and lower extremity amputation have shown significant regional variation in previous reports, 5, 7 with the exception of the Mountain region, we found only minor regional variation in the use of preamputation arterial imaging after adjustment for other characteristics. Although receipt of testing was associated with a prior visit with a vascular specialist, predominately cardiologists, it may fall to practicing cardiologists to drive national improvements in this category.
Our study has some limitations. First, the analysis only includes patients enrolled in fee-for-service Medicare, so the generalizability to patients not enrolled in fee-for-service Medicare is unclear. Second, the analysis did not capture data on unbilled bedside Doppler or ABI exams. It is unlikely, however, that these tests occur frequently in outpatient settings because of a lack of reimbursement. Furthermore, informal and nonstandard bedside physiological testing in the face of impending amputation is fraught with issues of quality control and ensuring adequate operator qualifications. Third, we limited our assessment of preamputation arterial testing to 12 months before amputation. However, previous studies have assessed vascular care during longer intervals before amputation and found little difference in their effect sizes. 33 Indeed, our findings changed little when we increased our ascertainment period to ≤24 months before amputation.
In conclusion, many patients, both with and without known PAD, undergo lower extremity amputation without arterial testing in the year before amputation. Given the morbidity, mortality, and quality of life costs associated with lower extremity amputation, current guidelines suggest that ABI measurement should be part of the initial examination of patients considered for nontraumatic lower extremity amputation. Consistent with under-recognition and undertreatment of PAD in women, women are less likely to receive preamputation arterial testing. Given that cardiologists see the most patients who will go on to need lower extremity amputation, practicing cardiologists will be responsible for increasing the frequency of preamputation arterial testing. Future work should focus on delineating the relationship between arterial testing and attempted revascularization, as well as arterial testing and mortality in patients undergoing lower extremity amputation. 
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